• Discover Astex
    • Our Mission & Values
    • Our Leadership Team
    • Research Fellows
    • Our History
    • Corporate Social Responsibility
  • R&D
    • Clinical Pipeline
    • Pyramid™ Discovery Platform
    • Oncology and CNS Discovery
    • Sustaining Innovation Postdocs
  • Partnering
  • Our People & Culture
    • Career Opportunities
  • Media
    • Press Releases
    • Conferences & Meetings
    • Presentations & Publications
    • Interactive Scientific Resources
      • Interactive Software
    • Astex in the News
  • Contact
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu
You are here: Home1 / 20062 / SuperGen Announces Achievement of $20 Million Dacogen™ (decitabine) Injection M...

SuperGen Announces Achievement of $20 Million Dacogen™ (decitabine) Injection Milestone

26 May 2006/in 2006, News

SuperGen Announces Achievement of $20 Million Dacogen™ (decitabine) Injection Milestone

https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg 0 0 webadmin https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg webadmin2006-05-26 13:57:352016-11-28 13:57:57SuperGen Announces Achievement of $20 Million Dacogen™ (decitabine) Injection Milestone

© Astex Pharmaceuticals
All rights reserved

astex

Useful links

  • Home
  • Sitemap
  • Privacy Policy
  • Terms of Use
  • Legal
  • LinkedIn

Member of the Otsuka Group

A selection of photos on this website
is courtesy of Valerio Berdini

Link to: SuperGen to Webcast Analyst & Investor Day Link to: SuperGen to Webcast Analyst & Investor Day SuperGen to Webcast Analyst & Investor Day Link to: SuperGen Receives U.S. Patent For Nipent® (Pentostatin For Injection) Link to: SuperGen Receives U.S. Patent For Nipent® (Pentostatin For Injection) SuperGen Receives U.S. Patent For Nipent® (Pentostatin For Injection)
Scroll to top Scroll to top Scroll to top
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.